Free Access
| Issue |
J Extra Corpor Technol
Volume 40, Number 2, June 2008
|
|
|---|---|---|
| Page(s) | 130 - 134 | |
| DOI | https://doi.org/10.1051/ject/200840130 | |
| Published online | 15 June 2008 | |
- Bauer TL, Arepaly G, Konkele BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation. 1997;95:1242–6. [CrossRef] [PubMed] [Google Scholar]
- Webb DP, Vinas MS, Drinkwater DC, et al. The use of r-hirudin during cardiopulmonary bypass in a patient with heparin induced thrombocytopenia. J Extra Corpor Technol. 2000;32:107–10. [Google Scholar]
- Jang IK, Hursting MJ. When heparins promote thrombosis: Review of heparin-induced thrombocytopenia. Circulation. 2005;111:2671–83. [CrossRef] [PubMed] [Google Scholar]
- Murphy GS, Marymont JH. Alternative anticoagulation manage-ment strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery. J Cardio Vasc Anesth. 2007;21:113–26. [CrossRef] [Google Scholar]
- Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Hematol. 2003;121:535–55. [CrossRef] [Google Scholar]
- Yeh RW, Jang IK. Argatroban: update. Am Heart J. 2006;151:1131–8. [CrossRef] [PubMed] [Google Scholar]
- Kathiresan S, Shiomura J, Jang IK. Argatroban. J Thromb Thrombolysis. 2002;13:41–7. [CrossRef] [PubMed] [Google Scholar]
- Fareed J, Jeske WP. Small-molecule direct antithrombins. Argatroban. Best Pract Res Clin Haematol. 2004;17:127–38. [CrossRef] [Google Scholar]
- Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulation therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838–43. [CrossRef] [PubMed] [Google Scholar]
- Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest. 2006;129:1167–75. [CrossRef] [PubMed] [Google Scholar]
- Lewis BE, Wallis DE, Hursting MJ. Effects of Argatroban therapy, demographics variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest. 2006;129:1407–16. [CrossRef] [PubMed] [Google Scholar]
- Koster A, Buz S, Hetzer R, et al. Anticoagulation with Argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-EO3 trial. J Thorac Cardiovasc Surg. 2006;132:699–700. [CrossRef] [Google Scholar]
- Mejak B, Giacomuzzi C, Heller E, et al. Argatroban usage for anti-coagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia. J Extra Corpor Technol. 2004;36:178–81. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
- Murray PT, Hursting MJ. Heparin-induced thrombocytopenia in patients administered heparin solely for hemodialysis. Ren Fail. 2006;28:537–9. [CrossRef] [PubMed] [Google Scholar]
- Thiele H, Lauer B, Hambrecht R. Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation. 2001;104:2917–22. [CrossRef] [PubMed] [Google Scholar]
- Kar B, Adkins LE, Civitello AB, et al. Clinical experience with the TandemHeart percutaneous ventricular assist device. Tex Heart Inst J. 2006;33:111–5. [PubMed] [Google Scholar]
- Thiele H, Sick P, Boudriot E. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2005;26:1276–83. [CrossRef] [PubMed] [Google Scholar]
- Boehmer JP, Popjes E. Cardiac failure. Crit Care Med. 2006;34:S268–77. [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.